Summit Therapeutics PLC Net Income
| SMMT Stock | USD 14.96 0.33 2.26% |
As of the 15th of February 2026, Summit Therapeutics has the Coefficient Of Variation of (1,670), variance of 14.88, and Risk Adjusted Performance of (0.04). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Summit Therapeutics PLC, as well as the relationship between them.
Summit Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 6.4 K | Earnings Share (1.25) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -199.2 M | -189.2 M | |
| Net Loss | -199.2 M | -209.1 M | |
| Net Loss | -70.9 M | -67.4 M | |
| Net Loss | (0.35) | (0.37) | |
| Net Income Per E B T | 0.90 | 0.77 |
Summit | Net Income | Build AI portfolio with Summit Stock |
The evolution of Net Income for Summit Therapeutics PLC provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Summit Therapeutics compares to historical norms and industry peers.
Latest Summit Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Summit Therapeutics PLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Summit Therapeutics PLC financial statement analysis. It represents the amount of money remaining after all of Summit Therapeutics PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Summit Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Summit Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (221.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Summit Net Income Regression Statistics
| Arithmetic Mean | (90,574,576) | |
| Coefficient Of Variation | (170.59) | |
| Mean Deviation | 101,453,238 | |
| Median | (24,337,000) | |
| Standard Deviation | 154,511,296 | |
| Sample Variance | 23873.7T | |
| Range | 624.8M | |
| R-Value | (0.61) | |
| Mean Square Error | 15898.9T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (18,753,859) | |
| Total Sum of Squares | 381979.8T |
Summit Net Income History
Other Fundumenentals of Summit Therapeutics PLC
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Summit Therapeutics Net Income component correlations
Summit Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Summit Therapeutics is extremely important. It helps to project a fair market value of Summit Stock properly, considering its historical fundamentals such as Net Income. Since Summit Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Summit Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Summit Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Summit introduce new products? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Summit Therapeutics PLC's market price often diverges from its book value, the accounting figure shown on Summit's balance sheet. Smart investors calculate Summit Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Summit Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Summit Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Summit Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Summit Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Summit Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Summit Therapeutics PLC or generate 0.0% return on investment in Summit Therapeutics over 90 days. Summit Therapeutics is related to or competes with Roivant Sciences, BridgeBio Pharma, Revolution Medicines, Ascendis Pharma, Ionis Pharmaceuticals, EXACT Sciences, and Royalty Pharma. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infect... More
Summit Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Summit Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Summit Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 23.61 | |||
| Value At Risk | (5.97) | |||
| Potential Upside | 6.49 |
Summit Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Summit Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Summit Therapeutics' standard deviation. In reality, there are many statistical measures that can use Summit Therapeutics historical prices to predict the future Summit Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.10) |
Summit Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 2.74 | |||
| Coefficient Of Variation | (1,670) | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.88 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 23.61 | |||
| Value At Risk | (5.97) | |||
| Potential Upside | 6.49 | |||
| Skewness | (0.13) | |||
| Kurtosis | 1.9 |
Summit Therapeutics PLC Backtested Returns
Summit Therapeutics PLC owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0334, which indicates the firm had a -0.0334 % return per unit of risk over the last 3 months. Summit Therapeutics PLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Summit Therapeutics' Coefficient Of Variation of (1,670), variance of 14.88, and Risk Adjusted Performance of (0.04) to confirm the risk estimate we provide. The entity has a beta of 2.4, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Summit Therapeutics will likely underperform. At this point, Summit Therapeutics PLC has a negative expected return of -0.13%. Please make sure to validate Summit Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Summit Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.3 |
Weak reverse predictability
Summit Therapeutics PLC has weak reverse predictability. Overlapping area represents the amount of predictability between Summit Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Summit Therapeutics PLC price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Summit Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 2.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Summit Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Summit Therapeutics PLC reported net income of (221.31 Million). This is 164.85% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 138.76% higher than that of the company.
Summit Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Summit Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics of similar companies.Summit Therapeutics is currently under evaluation in net income category among its peers.
Summit Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Summit Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Summit Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Summit Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Summit Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Summit Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Summit Therapeutics' value.| Shares | Apeiron Capital Ltd | 2025-06-30 | 1.2 M | Aberdeen Group Plc | 2025-06-30 | 1.1 M | Polar Capital Holdings Plc | 2025-06-30 | 1000 K | Polymer Capital Management (hk) Ltd | 2025-06-30 | 890 K | Fiera Capital Corporation | 2025-06-30 | 782.8 K | Rock Springs Capital Management Lp | 2025-06-30 | 710 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 642 K | Bank Of America Corp | 2025-06-30 | 566.1 K | Millennium Management Llc | 2025-06-30 | 556 K | Baker Bros Advisors Lp | 2025-06-30 | 33.7 M | Fmr Inc | 2025-06-30 | 9.2 M |
Summit Fundamentals
| Return On Equity | -2.92 | ||||
| Return On Asset | -1.53 | ||||
| Current Valuation | 10.9 B | ||||
| Shares Outstanding | 744.44 M | ||||
| Shares Owned By Insiders | 86.05 % | ||||
| Shares Owned By Institutions | 14.37 % | ||||
| Number Of Shares Shorted | 36.96 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | (212.85 M) | ||||
| Net Income | (221.31 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 7.22 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (142.11 M) | ||||
| Short Ratio | 12.11 X | ||||
| Earnings Per Share | (1.25) X | ||||
| Target Price | 32.9 | ||||
| Number Of Employees | 159 | ||||
| Beta | -1.43 | ||||
| Market Capitalization | 11.14 B | ||||
| Total Asset | 435.56 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 382.02 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
| Net Asset | 435.56 M |
About Summit Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Summit Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.